In this review:
General principles for the treatment of MS and NMOSD
Pathology of early and late MS and disease phenotype
Contribution of post-marketing studies
Should we change treatment strategies?
Environmental control of astrocyte activities in CNS inflammation
Risk factors for MS in Japanese people
High-efficacy humanised monoclonal antibodies in MS
Clinical features of MOG-Ab+ disease
Quantitative MRI reporting in MS clinical practice
MS Performance Tool as a clinical tool
Ocrelizumab extended clinical trial data
Please login below to download this issue (PDF)